



The **NGAL** Test

For your clinical chemistry analyzer

EARLY DIAGNOSIS OF ACUTE KIDNEY INJURY

NGAL is a novel biomarker for diagnosing acute kidney injury (AKI). The key advantage of NGAL is that it responds earlier than other renal status markers like serum creatinine and shows a proportionate response to injury. NGAL determination thus permits the early diagnosis and prognostic stratification of acute kidney injury.

“ NGAL both in urine and plasma is an excellent early marker of AKI with an area under the receiver operator characteristic curve (AUC) in the range of 0.9 ”

Ronco C, Crit Care 2007

“ Monitoring of serum NGAL levels may allow us to predict renal graft recovery ”

Kusaka M et al, Cell Transplant 2008

“ NGAL can be used from the 1st day of injury as a reliable predictor of early AKI in multi-trauma patients ”

Makris K et al, Clin Chem Lab Med 2009



The NGAL Test*


The NGAL Test is based on the principle of turbidimetry, which is used in a wide range of automated clinical chemistry analyzers. Turbidimetry is simple, fast and accurate, and addresses the wide demand for urgent NGAL determination in both urine and plasma.

Measuring range	25 to 5,000 ng/mL
Security range	Up to 40,000 ng/mL
Specimens	Urine and EDTA plasma

The NGAL Test vs. ELISA

The turbidimetric NGAL Test results show an excellent correlation with the results from BioPorto's NGAL ELISA Kit.

40 urine samples from ICU patients selected to cover a wide range of different NGAL concentrations were measured by The NGAL Test and by BioPorto's NGAL ELISA Kit.




NGAL vs. RIFLE criteria

NGAL shows a proportionate response to kidney injury and is significantly increased in patients who develop acute renal failure.

Urine and plasma NGAL were measured in 135 consecutive ICU patients and the maximal values grouped according to the RIFLE criteria for AKI diagnosis.

Both urine and plasma NGAL values provide high diagnostic performance.



Clinical application

Measuring NGAL in urine or plasma gives you information on AKI status that you need for rapid clinical decision making e.g. in the following settings:

- » For monitoring critically ill patients in intensive care
- » As a powerful triage tool in the emergency room setting
- » For predictive evaluation in renal transplantation
- » For preventive information on damage caused by nephrotoxic contrast agents

* BioPorto's NGAL patent WO2006066587 covering the measurement of NGAL as a marker for acute kidney injury is issued in South Africa, New Zealand and Singapore and is approved for issue in Europe.



BioPorto Diagnostics A/S
Grusbakken 8
DK-2820 Gentofte
Denmark

Phone: (+45) 4529 0000
Fax: (+45) 4529 0001
E-mail: info@bioporto.com
Web: www.bioporto.com
www.ngal.com